InsiderPulse
Dashboard

PCVX

Vaxcyte, Inc.

Health CareRussell 2000

Vaxcyte, Inc. insider trading

Vaxcyte, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in San Carlos, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent PCVX insider transactions

4 insiders traded PCVX on the open market between Jun 26, 2026 and Sep 09, 2026 — 24 sales worth $4.6M, of which 18 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$4.6M

18 of 24 on a 10b5-1 plan

Net
−$4.6M
Insiders
4

Open-market purchases (code P) and sales (code S) from Vaxcyte, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every PCVX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

PCVX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded PCVX on the open market: 0 purchases and 182 sales worth $42.2M, 179 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 27 sales ($5.3M), by 5 insiders.

QuarterBoughtSold
Q2 2026—−$3.7M19 sales · all on a plan
Q1 2026—−$687.1K5 sales · all on a plan
Q4 2025—−$1M3 sales
Q3 2025——
Q2 2025——
Q1 2025—−$5.1M32 sales · all on a plan
Q4 2024—−$21.4M69 sales · all on a plan
Q3 2024—−$10.3M54 sales · all on a plan
Largest sale
−$4.2M of PCVX by Guggenhime Andrew (President And CFO) on Oct 18, 2024, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$505K

    Jun 26, 2026

    9,137 sh · $55.27

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$362.8K

    Jun 26, 2026

    6,683 sh · $54.28

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$360.1K

    Jun 26, 2026

    6,417 sh · $56.12

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$33.3K

    Jun 26, 2026

    602 sh · $55.30

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$19.7K

    Jun 26, 2026

    356 sh · $55.23

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$18.6K

    Jun 26, 2026

    332 sh · $55.99

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$17K

    Jun 26, 2026

    312 sh · $54.35

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$11.2K

    Jun 26, 2026

    207 sh · $54.22

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$10.7K

    Jun 26, 2026

    191 sh · $56.27

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$1.2M

    Jun 18, 2026

    22,236 sh · $52.50

  • Guggenhime Andrew10b5-1

    President And CFO

    −$530K

    Jun 18, 2026

    10,000 sh · $53.00

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$52.5K

    Jun 18, 2026

    1,000 sh · $52.50

  • Pickering Grant10b5-1

    Chief Executive Officer · Director

    −$11.8K

    Jun 18, 2026

    225 sh · $52.51

  • Wassil Jim10b5-1

    Chief Operating Officer

    −$96.3K

    Jun 01, 2026

    1,949 sh · $49.40

  • Wassil Jim10b5-1

    Chief Operating Officer

    −$15.1K

    Jun 01, 2026

    301 sh · $50.26

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Vaxcyte, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
San Carlos, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001649094
Previously filed as
SutroVax, Inc.

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought PCVX

What the stock actually did in the 90 days following each open-market purchase

Don't check PCVX — let it ping you

Get told the moment an insider moves on PCVX

Pro watches Vaxcyte, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add PCVX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track PCVX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read PCVX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

PTGXRVMDRYTMSMMTSNDXSRRKTGTXVERAVKTXXENEZLABATTO
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are PCVX insiders buying or selling?
Between Jun 26, 2026 and Sep 09, 2026, 4 Vaxcyte, Inc. insiders made no open-market purchases and 24 sales worth $4.6M, a net sale of $4.6M. 18 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much PCVX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Vaxcyte, Inc. insiders made no open-market purchases and 182 sales worth $42.2M. 179 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 27 sales ($5.3M). The largest sale was Guggenhime Andrew selling $4.2M on Oct 18, 2024.
What was the largest recent PCVX insider trade?
Dhaliwal Harpreet S. (Chief Technical Ops Officer) sold $935.1K of PCVX stock on Aug 05, 2026 at about $55.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy PCVX shares?
No open-market purchase by a Vaxcyte, Inc. insider appears in the filings from Jun 26, 2026 to Sep 09, 2026 — every recorded open-market transaction in that period was a sale.
Where does PCVX insider trading data come from?
From the Form 4 filings Vaxcyte, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.